Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone

Isoxyl (ISO) and thiacetazone (TAC) are two antitubercular prodrugs formerly used in the clinical treatment of tuberculosis. Although both prodrugs have recently been shown to kill Mycobacterium tuberculosis through the inhibition of the dehydration step of the type II fatty acid synthase pathway, their detailed mechanism of inhibition, the precise number of enzymes involved in their activation, and the nature of their activated forms remained unknown. This paper demonstrates that both ISO and TAC specifically and covalently react with a cysteine residue (Cys61) of the HadA subunit of the dehydratase, thereby inhibiting HadAB activity. The results unveil for the first time the nature of the active forms of ISO and TAC and explain the basis for the structure–activity relationship of and resistance to these thiourea prodrugs. The results further indicate that the flavin-containing monooxygenase EthA is most likely the only enzyme required for the activation of ISO and TAC in mycobacteria.

[1]  D. Ronning,et al.  Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen , 2013, Nature Communications.

[2]  L. Kremer,et al.  Synthesis, Antitubercular Activity and Mechanism of Resistance of Highly Effective Thiacetazone Analogues , 2013, PloS one.

[3]  H. R. Morbidoni,et al.  Mutations in the essential FAS II β‐hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii , 2012, Molecular microbiology.

[4]  L. Kremer,et al.  Point Mutations within the Fatty Acid Synthase Type II Dehydratase Components HadA or HadC Contribute to Isoxyl Resistance in Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[5]  P. Brennan,et al.  A Common Mechanism of Inhibition of the Mycobacterium tuberculosis Mycolic Acid Biosynthetic Pathway by Isoxyl and Thiacetazone* , 2012, The Journal of Biological Chemistry.

[6]  R. Read,et al.  Supplementary Materials for Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis , 2012 .

[7]  S. Cole,et al.  Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1. , 2012, Journal of the American Chemical Society.

[8]  D. Zerbib,et al.  The Mycobacterium Tuberculosis FAS-II Dehydratases and Methyltransferases Define the Specificity of the Mycolic Acid Elongation Complexes , 2011, PloS one.

[9]  E. J. North,et al.  The structure-activity relationship of urea derivatives as anti-tuberculosis agents. , 2011, Bioorganic & medicinal chemistry.

[10]  Vadim Makarov,et al.  Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. , 2010, Journal of the American Chemical Society.

[11]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[12]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[13]  W. Bishai,et al.  Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis , 2009, Molecular microbiology.

[14]  Paul Carroll,et al.  The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis , 2007, Proceedings of the National Academy of Sciences.

[15]  P. Brennan,et al.  Isoxyl Activation Is Required for Bacteriostatic Activity against Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[16]  James C. Sacchettini,et al.  Mechanism of thioamide drug action against tuberculosis and leprosy , 2007, The Journal of experimental medicine.

[17]  G. Besra,et al.  EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets , 2007, Antimicrobial Agents and Chemotherapy.

[18]  P. Ortiz de Montellano,et al.  Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. , 2006, Chemical research in toxicology.

[19]  D. Zerbib,et al.  The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. , 2005, Journal of molecular biology.

[20]  L. Mourey,et al.  Protein–protein interactions within the Fatty Acid Synthase‐II system of Mycobacterium tuberculosis are essential for mycobacterial viability , 2004, Molecular microbiology.

[21]  C. E. Barry,et al.  The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. , 2002, Tuberculosis.

[22]  L. Bekker,et al.  Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. D. Douglas,et al.  Antimycobacterial Activities of Isoxyl and New Derivatives through the Inhibition of Mycolic Acid Synthesis , 1999, Antimicrobial Agents and Chemotherapy.

[24]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[25]  F. Winder,et al.  Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. , 1971, Journal of general microbiology.

[26]  Talat Jabeena,et al.  Structural basis of inhibition of Mycobacterium tuberculosis DprE 1 by benzothiazinone inhibitors , 2012 .

[27]  M. Sternberg,et al.  Protein structure prediction on the Web: a case study using the Phyre server , 2009, Nature Protocols.